225 related articles for article (PubMed ID: 23657192)
1. The European Medicines Agency's plans for sharing data from clinical trials.
Groves T; Godlee F
BMJ; 2013 May; 346():f2961. PubMed ID: 23657192
[No Abstract] [Full Text] [Related]
2. A future for regulatory science in the European Union: the European Medicines Agency's strategy.
Hines PA; Janssens R; Gonzalez-Quevedo R; Lambert AIOM; Humphreys AJ
Nat Rev Drug Discov; 2020 May; 19(5):293-294. PubMed ID: 32235873
[No Abstract] [Full Text] [Related]
3. EU directive on clinical trials penalizes small sponsors.
Meldolesi A
Nat Biotechnol; 2003 Aug; 21(8):838. PubMed ID: 12894186
[No Abstract] [Full Text] [Related]
4. FDA and EMEA pool scientific advice.
Katsnelson A
Nat Biotechnol; 2004 Dec; 22(12):1490-1. PubMed ID: 15583642
[No Abstract] [Full Text] [Related]
5. European ombudsman questions European Medicines Agency over AbbVie redactions.
Watson R
BMJ; 2014 Nov; 349():g6904. PubMed ID: 25406123
[No Abstract] [Full Text] [Related]
6. Regulatory watch: Where do new medicines originate from in the EU?
Lincker H; Ziogas C; Carr M; Porta N; Eichler HG
Nat Rev Drug Discov; 2014 Feb; 13(2):92-3. PubMed ID: 24481298
[No Abstract] [Full Text] [Related]
7. European regulator is urged to release data on drugs approved in past 10 years.
Kmietowicz Z
BMJ; 2013 Sep; 347():f5905. PubMed ID: 24081901
[No Abstract] [Full Text] [Related]
8. Maine law requires drug companies to provide clinical trial data.
Appell D
J Natl Cancer Inst; 2005 Sep; 97(17):1246. PubMed ID: 16145043
[No Abstract] [Full Text] [Related]
9. Fostering EMA's transparency policy.
Banzi R; Bertele' V; Demotes-Mainard J; Garattini S; Gluud C; Kubiak C; Ohmann C
Eur J Intern Med; 2014 Oct; 25(8):681-4. PubMed ID: 25200801
[TBL] [Abstract][Full Text] [Related]
10. Transparency interrupted: the curtailment of the European Medicines Agency's Policy on access to documents.
Doshi P
JAMA Intern Med; 2013 Nov; 173(21):2009-11. PubMed ID: 23959623
[No Abstract] [Full Text] [Related]
11. Researchers see a need for speed in EU trial approvals.
Cressey D
Nat Med; 2008 Aug; 14(8):794. PubMed ID: 18685580
[No Abstract] [Full Text] [Related]
12. Regulatory challenges in the review of data from global clinical trials: the PMDA perspective.
Asano K; Tanaka A; Sato T; Uyama Y
Clin Pharmacol Ther; 2013 Aug; 94(2):195-8. PubMed ID: 23872835
[TBL] [Abstract][Full Text] [Related]
13. Germany opposes EU plans for regulating clinical trials owing to lack of ethical standards.
Tuffs A
BMJ; 2012 Oct; 345():e6640. PubMed ID: 23033377
[No Abstract] [Full Text] [Related]
14. [European drug policy: welcomed modernization but shortage of political proposals concerning industry and research].
Alván G
Lakartidningen; 2003 Oct; 100(44):3541-2. PubMed ID: 14651017
[No Abstract] [Full Text] [Related]
15. European drug agency to appeal ruling that it stop releasing trial data.
Hawkes N
BMJ; 2016 Sep; 354():i5331. PubMed ID: 27694255
[No Abstract] [Full Text] [Related]
16. Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars.
Gitter DM
Seton Hall Law Rev; 2011; 41(2):559-92. PubMed ID: 21739759
[No Abstract] [Full Text] [Related]
17. [The Medical Product Agency's work and economics--a comment].
Ahlqvist Rastad J; Salmonson T
Lakartidningen; 2003 Jan; 100(5):345. PubMed ID: 12607382
[No Abstract] [Full Text] [Related]
18. Drive for drugs leads to baby clinical trials.
Nature; 2006 Mar; 440(7083):406-7. PubMed ID: 16554774
[No Abstract] [Full Text] [Related]
19. Drug marketing exclusivity under United States and European Union law.
Junod V
Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347
[No Abstract] [Full Text] [Related]
20. Availability of comparative trials for the assessment of new medicines in the European Union at the moment of market authorization.
van Luijn JC; Gribnau FW; Leufkens HG
Br J Clin Pharmacol; 2007 Feb; 63(2):159-62. PubMed ID: 17166187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
